| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1006676802 |
| P356 | DOI | 10.1038/SJ.BMT.1700637 |
| P698 | PubMed publication ID | 9028553 |
| P5875 | ResearchGate publication ID | 245665711 |
| P2093 | author name string | Hayashi S | |
| Harada M | |||
| Mizuno S | |||
| Harada N | |||
| Tanimoto K | |||
| Okamura T | |||
| Niho Y | |||
| Shibuya T | |||
| Yamasaki K | |||
| Gondo H | |||
| Miyamoto T | |||
| Eto T | |||
| Teshima T | |||
| Takenaka K | |||
| Minamishima Y | |||
| Minematsu T | |||
| Nagafuji K | |||
| Fujisaki T | |||
| Osaki K | |||
| Matsuishi E | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cytomegalovirus | Q6946 |
| P304 | page(s) | 241-248 | |
| P577 | publication date | 1997-02-01 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group | |
| P478 | volume | 19 |
| Q73104302 | A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy |
| Q44130620 | CMV retinitis after allogeneic bone marrow transplantation: a report of five cases |
| Q74828383 | Clinical utility of capillary polymerase chain reaction for diagnosis of Cytomegalovirus pneumonia |
| Q37310186 | Construction and Evaluation of Cytomegalovirus DNA Quantification System with Real-Time Detection Polymerase Chain Reaction |
| Q42275611 | Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients |
| Q44603444 | Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation |
| Q77170463 | Cytomegalovirus infection in recipients of related and unrelated donor bone marrow transplants: no evidence of increased incidence in patients receiving unrelated donor grafts |
| Q37179131 | Cytomegalovirus pneumonia in hematopoietic stem cell recipients. |
| Q35223576 | Dextramer reagents are effective tools for quantifying CMV antigen-specific T cells from peripheral blood samples |
| Q42214333 | Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation |
| Q36626424 | Donor killer immunoglobulin-like receptor genes and reactivation of cytomegalovirus after HLA-matched hematopoietic stem-cell transplantation: HLA-C allotype is an essential cofactor |
| Q40569370 | Early infections in adult patients undergoing unrelated donor cord blood transplantation. |
| Q34989242 | Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides |
| Q43434940 | Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor |
| Q90459507 | Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation |
| Q43586526 | High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allograft recipients at low risk of CMV. |
| Q78372494 | Human herpesvirus 6 infection and cytomegalovirus-specific lymphoproliferative responses in allogeneic stem cell transplant recipients |
| Q42219821 | Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease |
| Q47623866 | Infections in adults undergoing unrelated donor bone marrow transplantation |
| Q53636518 | Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea. |
| Q40595159 | Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation |
| Q84042992 | Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients |
| Q43536885 | Kinetics of myeloid and lymphocyte recovery and infectious complications after unrelated umbilical cord blood versus HLA-matched unrelated donor allogeneic transplantation in adults |
| Q51348958 | L-index as a novel index to evaluate both the intensity and duration of lymphopenia after allogeneic hematopoietic stem cell transplantation. |
| Q74312125 | Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors |
| Q44214552 | Monitoring cytomegalovirus infection by antigenemia assay and two distinct plasma real-time PCR methods after hematopoietic stem cell transplantation |
| Q43973082 | Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction |
| Q34294774 | Opportunistic infections after blood and marrow transplantation |
| Q45367721 | Opportunistic virus DNA levels after pediatric stem cell transplantation: serostatus matching, anti-thymocyte globulin, and total body irradiation are additive risk factors. |
| Q46160352 | Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients |
| Q43583148 | Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan |
| Q44245126 | Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation |
| Q34244404 | Reactivation of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation |
| Q73586578 | Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT |
| Q42989389 | Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation |
| Q35900978 | Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis |
| Q43635761 | The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. |
Search more.